Vaishali Pharma (VAISHALI) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
20 Nov, 2025Executive summary
Audited financial results for the year ended March 31, 2025, were approved by the Board on May 28, 2025.
The audit opinion is qualified due to material uncertainty regarding recoverability of significant trade receivables, deposits, loans, and advances.
Financial highlights
Revenue from operations for FY25 was ₹9,788.20 lakh, up from ₹8,176.35 lakh year-over-year.
Net profit for FY25 was ₹81.73 lakh, compared to ₹71.89 lakh in FY24.
Total comprehensive income for FY25 was ₹82.02 lakh.
Basic and diluted EPS for FY25 were ₹0.31 and ₹0.31, respectively.
Outlook and guidance
The auditor highlighted material uncertainty regarding the recoverability of certain receivables and advances, which may impact future results.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vaishali Pharma
- Q1 FY27 net profit rose to ₹148.97 lakh standalone, with consolidation of Kesar Pharma boosting group results.VAISHALI
Q1 26/27 - Strong revenue and profit growth, with new associate consolidation and auditor caution on receivables.VAISHALIQ4 25/26
- Q3 FY26 profit rose sequentially, preferential issue to raise ₹12.25 crore approved.VAISHALIQ3 25/26
- Strong revenue and profit growth with improved margins and positive operating cash flow.VAISHALIQ2 25/26
- Q1 FY26 saw higher revenue but lower net profit and EPS amid rising expenses.VAISHALIQ1 25/26
- Revenue and net profit rose year-over-year, with strong equity growth and robust financing inflows.VAISHALIQ2 24/25
- Q1 FY25 saw higher revenue, a return to profit, and increased share capital.VAISHALIQ1 24/25
- Q3 FY25 revenue was flat, but net profit fell on higher costs; auditors found no misstatements.VAISHALIQ3 24/25